Maria Margareta Cosnarovici, Rodica Cosnarovici, Doina Piciu
{"title":"儿童脑肿瘤患者的治疗效果--一个中心 18 年来的经验。","authors":"Maria Margareta Cosnarovici, Rodica Cosnarovici, Doina Piciu","doi":"10.15386/mpr-2571","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Tumors of the central nervous system represent the main cause of death by cancer in children. The diagnosis and molecular classification of these neoplasms have seen great improvement in the past years, due to ongoing genomic advances. In general, the treatment consists of surgery, radiation therapy and chemotherapy. However, the currently available pharmacological treatment options have limited effectiveness due to the particular characteristics of the blood-brain barrier.</p><p><strong>Methods: </strong>We decided to study the therapeutic results in children treated for brain tumors in the Cluj-Napoca \"Prof. dr. Ion Chiricuta\" Oncology Institute, between 2001 and 2018, in order to provide a more accurate understanding of the disease and the available therapeutic options in our center.</p><p><strong>Results: </strong>Out of the 207 cases included in this study, we recorded 98 deaths (47.3%). This is significantly less than the 5-year survival rate recorded in the US between 2012 and 2018 (74.9%). There are many factors that could explain the low survival rate, such as a very late diagnosis, the inability to implement innovative radiation therapy techniques until 2018, and the fact that between 2001 and 2010 the chemotherapy regimens in our center were not as effective as the more recent ones.</p><p><strong>Conclusions: </strong>The therapeutic results recorded in this study are similar to those in other middle-income countries, however, the available treatment options for pediatric brain tumors are not as effective as those currently in use for other pediatric and adult malignancies.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"97 1","pages":"56-63"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852121/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic results in children with brain tumors - a single center experience over 18 years.\",\"authors\":\"Maria Margareta Cosnarovici, Rodica Cosnarovici, Doina Piciu\",\"doi\":\"10.15386/mpr-2571\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Tumors of the central nervous system represent the main cause of death by cancer in children. The diagnosis and molecular classification of these neoplasms have seen great improvement in the past years, due to ongoing genomic advances. In general, the treatment consists of surgery, radiation therapy and chemotherapy. However, the currently available pharmacological treatment options have limited effectiveness due to the particular characteristics of the blood-brain barrier.</p><p><strong>Methods: </strong>We decided to study the therapeutic results in children treated for brain tumors in the Cluj-Napoca \\\"Prof. dr. Ion Chiricuta\\\" Oncology Institute, between 2001 and 2018, in order to provide a more accurate understanding of the disease and the available therapeutic options in our center.</p><p><strong>Results: </strong>Out of the 207 cases included in this study, we recorded 98 deaths (47.3%). This is significantly less than the 5-year survival rate recorded in the US between 2012 and 2018 (74.9%). There are many factors that could explain the low survival rate, such as a very late diagnosis, the inability to implement innovative radiation therapy techniques until 2018, and the fact that between 2001 and 2010 the chemotherapy regimens in our center were not as effective as the more recent ones.</p><p><strong>Conclusions: </strong>The therapeutic results recorded in this study are similar to those in other middle-income countries, however, the available treatment options for pediatric brain tumors are not as effective as those currently in use for other pediatric and adult malignancies.</p>\",\"PeriodicalId\":18438,\"journal\":{\"name\":\"Medicine and Pharmacy Reports\",\"volume\":\"97 1\",\"pages\":\"56-63\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852121/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine and Pharmacy Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15386/mpr-2571\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine and Pharmacy Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15386/mpr-2571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:中枢神经系统肿瘤是儿童癌症死亡的主要原因。由于基因组学的不断进步,这些肿瘤的诊断和分子分类在过去几年有了很大的改进。一般来说,治疗包括手术、放疗和化疗。然而,由于血脑屏障的特殊性,目前可用的药物治疗方案效果有限:我们决定研究克卢日-纳波卡 "Prof. dr. Ion Chiricuta "肿瘤研究所在 2001 年至 2018 年间对脑肿瘤患儿的治疗效果,以便更准确地了解该疾病以及本中心现有的治疗方案:在纳入本研究的 207 个病例中,我们记录了 98 例死亡病例(47.3%)。这明显低于美国在2012年至2018年期间记录的5年生存率(74.9%)。有很多因素可以解释存活率低的原因,如诊断非常晚、直到2018年才开始采用创新的放射治疗技术,以及2001年至2010年期间,我们中心的化疗方案不如最近的化疗方案有效等:本研究记录的治疗结果与其他中等收入国家的治疗结果相似,但是,小儿脑肿瘤的现有治疗方案不如其他小儿和成人恶性肿瘤的现有治疗方案有效。
Therapeutic results in children with brain tumors - a single center experience over 18 years.
Background and aims: Tumors of the central nervous system represent the main cause of death by cancer in children. The diagnosis and molecular classification of these neoplasms have seen great improvement in the past years, due to ongoing genomic advances. In general, the treatment consists of surgery, radiation therapy and chemotherapy. However, the currently available pharmacological treatment options have limited effectiveness due to the particular characteristics of the blood-brain barrier.
Methods: We decided to study the therapeutic results in children treated for brain tumors in the Cluj-Napoca "Prof. dr. Ion Chiricuta" Oncology Institute, between 2001 and 2018, in order to provide a more accurate understanding of the disease and the available therapeutic options in our center.
Results: Out of the 207 cases included in this study, we recorded 98 deaths (47.3%). This is significantly less than the 5-year survival rate recorded in the US between 2012 and 2018 (74.9%). There are many factors that could explain the low survival rate, such as a very late diagnosis, the inability to implement innovative radiation therapy techniques until 2018, and the fact that between 2001 and 2010 the chemotherapy regimens in our center were not as effective as the more recent ones.
Conclusions: The therapeutic results recorded in this study are similar to those in other middle-income countries, however, the available treatment options for pediatric brain tumors are not as effective as those currently in use for other pediatric and adult malignancies.